newsfilter
← Latest News
GlobeNewswire·

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers